1. Home
  2. COYA vs VANI Comparison

COYA vs VANI Comparison

Compare COYA & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coya Therapeutics Inc.

COYA

Coya Therapeutics Inc.

N/A

Current Price

$4.77

Market Cap

102.7M

Sector

Health Care

ML Signal

N/A

Logo Vivani Medical Inc. (DE)

VANI

Vivani Medical Inc. (DE)

N/A

Current Price

$1.22

Market Cap

119.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
COYA
VANI
Founded
2020
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.7M
119.0M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
COYA
VANI
Price
$4.77
$1.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
3
Target Price
★ $15.21
$3.83
AVG Volume (30 Days)
130.8K
★ 180.5K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $7,945,753.00
$4,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$387.14
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 123.57
N/A
52 Week Low
$3.71
$0.92
52 Week High
$7.75
$1.92

Technical Indicators

Market Signals
Indicator
COYA
VANI
Relative Strength Index (RSI) 54.67 44.74
Support Level $4.42 $1.24
Resistance Level $5.17 $1.25
Average True Range (ATR) 0.26 0.04
MACD 0.02 0.00
Stochastic Oscillator 65.69 53.00

Price Performance

Historical Comparison
COYA
VANI

About COYA Coya Therapeutics Inc.

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.

About VANI Vivani Medical Inc. (DE)

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

Share on Social Networks: